BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1368@pharmaconomics
DTSTAMP:20260707T034858Z
DTSTART;VALUE=DATE:20251231
DTEND;VALUE=DATE:20260101
SUMMARY:PHVS Phase 3 — deucrictibant
DESCRIPTION:Phase 3 trial results for deucrictibant in hereditary angioedema (HAE) are due Dec 31\, 2025. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1830487/000183048726000012/phvs-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/1368
URL:https://www.pharmaconomics.com/e/1368
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:PHVS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR